Search hospitals > Oklahoma > Oklahoma City
University of Oklahoma Health Sciences Center
Claim this profileOklahoma City, Oklahoma 73104
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Ovarian Cancer
1225 reported clinical trials
90 medical researchers
Summary
University of Oklahoma Health Sciences Center is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Ovarian Cancer and other specialties. University of Oklahoma Health Sciences Center is involved with conducting 1,225 clinical trials across 1,276 conditions. There are 90 research doctors associated with this hospital, such as Rene Y. McNall-Knapp, Debra L. Richardson, Kathleen Moore, M.D., MS, and Raid Aljumaily.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage II
Top PIs
Rene Y. McNall-KnappUniversity of Oklahoma Health Sciences Center7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
71 reported clinical trials
126 drugs studied
Debra L. RichardsonUniversity of Oklahoma Health Sciences Center2 years of reported clinical research
Expert in Ovarian Cancer
Expert in Cancer
32 reported clinical trials
51 drugs studied
Kathleen Moore, M.D., MSUniversity of Oklahoma Health Sciences Center1 year of reported clinical research
Expert in Ovarian Cancer
Expert in Ovarian Tumors
29 reported clinical trials
81 drugs studied
Raid AljumailyUniversity of Oklahoma Health Sciences Center7 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
24 reported clinical trials
40 drugs studied
Clinical Trials running at University of Oklahoma Health Sciences Center
Esophageal Adenocarcinoma
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Lung Cancer
Esophageal Carcinoma
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Esophageal Cancer
Gastric Cancer
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Proton Therapy vs Photon Radiation
for Esophageal Cancer
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Recruiting2 awards Phase 31 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Oklahoma Health Sciences Center?
University of Oklahoma Health Sciences Center is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Cancer, Recurrence, Tumors, Leukemia, Ovarian Cancer and other specialties. University of Oklahoma Health Sciences Center is involved with conducting 1,225 clinical trials across 1,276 conditions. There are 90 research doctors associated with this hospital, such as Rene Y. McNall-Knapp, Debra L. Richardson, Kathleen Moore, M.D., MS, and Raid Aljumaily.
Where is University of Oklahoma Health Sciences Center located?
The University of Oklahoma Health Sciences Center hospital is located at 700 NE 13th St, Oklahoma City, OK 73104, at the northwest corner of the intersection of NE 13th St and Lincoln Blvd.
Who should I call to ask about financial aid or insurance network?
The University of Oklahoma Health Sciences Center (OUHSC) provides financial assistance for eligible patients needing emergency or medically necessary care. Patients can apply for this assistance via the OUHSC website and are advised to confirm their insurance coverage by contacting their physician's office directly. For billing inquiries related to OU Health Physicians Tulsa, contact (918) 660-3650 or (918) 619-4400 for assistance in Spanish.
What insurance does University of Oklahoma Health Sciences Center accept?
The University of Oklahoma Health Sciences Center (OUHSC) and OU Health Physicians accept a broad spectrum of insurance plans, including but not limited to Aetna, Blue Cross Blue Shield, Cigna Healthcare, United Healthcare, and MultiPlan/PHCS. Coverage by some plans may vary by location, notably between Oklahoma City and Tulsa. Patients are advised to verify their insurance acceptance with the specific physician's office and consult OU Health hospitals and ERs for comprehensive insurance information.
What awards or recognition has University of Oklahoma Health Sciences Center received?
The University of Oklahoma Health Sciences Center, located in Oklahoma City, Oklahoma, is a premier healthcare research institution, with researchers securing over $140 million in sponsored funding annually since 2017. It houses the Stephenson Cancer Center, the only National Cancer Institute (NCI)-Designated Cancer Center in Oklahoma, offering access to the latest investigational drugs and clinical trials for cancer treatment. Additionally, the Harold Hamm Diabetes Center provides extensive clinical trials and volunteer opportunities for diabetes research.